Transarterial chemoembolization and radioembolization

Seminars in Liver Disease

Volumn 34, Issue 4, 2014, Pages 435-443

  Sangro, Bruno ^a   Salem, Riad ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

drug eluting bead transarterial chemoembolization; radioembolization; selective internal radiation therapy; transarterial chemoembolization; yttrium

Indexed keywords

ANTINEOPLASTIC AGENT; MICROSPHERE; NANOBEAD; RADIOPHARMACEUTICAL AGENT;

ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CHOLECYSTITIS; DRUG ELUTING STENT; HUMAN; INTESTINE ULCER; LIVER CELL CARCINOMA; LIVER INJURY; PNEUMONIA; PRIORITY JOURNAL; RADIOEMBOLIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ADVERSE EFFECTS; ARTIFICIAL EMBOLISM; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PROCEDURES; VASCULARIZATION;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; PATIENT SELECTION; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84928534285     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1394142     Document Type: Article

References (77)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin: 2011; 61 2 69 90
2. Bruix J., Sherman M.; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology: 2005; 42 5 1208 1236
3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol: 2012; 56 4 908
4. Villanueva A., Hernandez-Gea V., Llovet J. M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol: 2013; 10 1 34 42
5. Solomon B., Soulen M. C., Baum R. A., Haskal Z. J., Shlansky-Goldberg R. D., Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol: 1999; 10 6 793 798
6. Kan Z., McCuskey P. A., Wright K. C., Wallace S. Role of Kupffer cells in iodized oil embolization. Invest Radiol: 1994; 29 11 990 993
7. Bilbao J. I., de Luis E., García de Jalón J. A., et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol: 2008; 19 11 1625 1638
8. Chang J. M., Tzeng W. S., Pan H. B., Yang C. F., Lai K. H. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer: 1994; 74 9 2449 2453
9. Kawai S., Okamura J., Ogawa M., et al. The Cooperative Study Group for Liver Cancer Treatment of Japan. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma- A comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). Cancer Chemother Pharmacol: 1992; 31 (Suppl): S1 S6
10. Cammà C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology: 2002; 224 1 47 54
11. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol: 2007; 30 1 6 25
12. Raoul J. L., Sangro B., Forner A., et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev: 2011; 37 3 212 220
13. Llovet J. M., Real M. I., Montaña X., et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet: 2002; 359 9319 1734 1739
14. Lo C. M., Ngan H., Tso W. K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology: 2002; 35 5 1164 1171
15. Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology: 2003; 37 2 429
16. Lewandowski R. J., Mulcahy M. F., Kulik L. M., et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology: 2010; 255 3 955 965
17. Meyer T., Kirkwood A., Roughton M., et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer: 2013; 108 6 1252 1259
18. Lammer J., Malagari K., Vogl T., et al. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol: 2010; 33 1 41 52
19. Sieghart W., Hucke F., Pinter M., et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology: 2013; 57 6 2261 2273
20. Malagari K., Pomoni M., Moschouris H., et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol: 2012; 35 5 1119 1128
21. Burrel M., Reig M., Forner A., et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol: 2012; 56 6 1330 1335
22. Salem R., Lewandowski R. J., Mulcahy M. F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology: 2010; 138 1 52 64
23. Mazzaferro V., Sposito C., Bhoori S., et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology: 2013; 57 5 1826 1837
24. Hilgard P., Hamami M., Fouly A. E., et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology: 2010; 52 5 1741 1749
25. Sangro B., Carpanese L., Cianni R., et al. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology: 2011; 54 3 868 878
26. Takayasu K., Arii S., Ikai I., et al. Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology: 2006; 131 2 461 469
27. O'Suilleabhain C. B., Poon R. TP, Yong J. L., Ooi G. C., Tso W. K., Fan S. T. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg: 2003; 90 3 325 331
28. Poon R. T., Ngan H., Lo C. M., Liu C. L., Fan S. T., Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol: 2000; 73 2 109 114
29. Katyal S., Oliver J. H., Peterson M. S., Chang P. J., Baron R. L., Carr B. I. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol: 2000; 175 6 1665 1672
30. Bronowicki J. P., Vetter D., Dumas F., et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer: 1994; 74 1 16 24
31. Herber S. CA, Otto G., Schneider J., et al. Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol: 2008; 190 4 1035 1042
32. Lladó L., Virgili J., Figueras J., et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer: 2000; 88 1 50 57
33. Wang J-H, Changchien C-S, Hu T-H., et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer: 2008; 44 7 1000 1006
34. Hsu K-F, Chu C-H, Chan D-C., et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol: 2012; 81 3 466 471
35. Chen C-H, Hu F-C, Huang G-T., et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. Eur J Cancer: 2009; 45 9 1630
36. Ho M-C, Huang G-T, Tsang Y-M., et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol: 2009; 16 4 848 855
37. Moreno-Luna L. E., Yang J. D., Sanchez W., et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol: 2013; 36 3 714 723
38. Salem R., Lewandowski R. J., Kulik L., et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology: 2011; 140 2 497 507, e2
39. Jung E. S., Kim J. H., Yoon E. L., et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol: 2013; 58 6 1181 1187
40. Luo J., Guo R-P, Lai E. CH., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol: 2011; 18 2 413 420
41. Chung G. E., Lee J-H, Kim H. Y., et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology: 2011; 258 2 627 634
42. Iñarrairaegui M., Thurston K. G., Bilbao J. I., et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol: 2010; 21 8 1205 1212
43. Huo T-I, Wu J-C, Lee P-C, Chang F-Y, Lee S-D. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int: 2004; 24 3 210 215
44. Kim K. M., Kim J. H., Park I. S., et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol: 2009; 24 5 806 814
45. Chung J. W., Park J. H., Han J. K., et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology: 1996; 198 1 33 40
46. Pietrosi G., Miraglia R., Luca A., et al. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. J Vasc Interv Radiol: 2009; 20 7 896 902
47. Yu J-S, Kim K. W., Jeong M-G, Lee D. H., Park M-S, Yoon S-W. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol: 2002; 25 4 270 274
48. Xia J., Ren Z., Ye S., et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol: 2006; 59 3 407 412
49. Belli L., Magistretti G., Puricelli G. P., Damiani G., Colombo E., Cornalba G. P. Arteritis following intra-arterial chemotherapy for liver tumors. Eur Radiol: 1997; 7 3 323 326
50. Varela M., Real M. I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol: 2007; 46 3 474 481
51. Lencioni R., de Baere T., Burrel M., et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol: 2012; 35 5 980 985
52. Grosso M., Vignali C., Quaretti P., et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol: 2008; 31 6 1141 1149
53. Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol: 2010; 33 3 541 551
54. Malagari K., Pomoni M., Spyridopoulos T. N., et al. Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol: 2011; 34 4 774 785
55. Vogl T. J., Lammer J., Lencioni R., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol: 2011; 197 4 W562-70
56. Kennedy A., Coldwell D., Sangro B., Wasan H., Salem R. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol: 2012; 35 1 91 99
57. Kulik L. M., Carr B. I., Mulcahy M. F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology: 2008; 47 1 71 81
58. Salem R., Gilbertsen M., Butt Z., et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol: 2013; 11 10 1358 1365, e1
59. Lewandowski R. J., Kulik L. M., Riaz A., et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant: 2009; 9 8 1920 1928
60. Llovet J. M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 4 378 390
61. Cheng A-L, Kang Y-K, Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol: 2009; 10 1 25 34
62. Bilbao J. I., de Martino A., de Luis E., et al. Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc Intervent Radiol: 2009; 32 4 727 736
63. Memon K., Kulik L., Lewandowski R. J., et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol: 2013; 58 1 73 80
64. Bruix J., Raoul J-L, Sherman M., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol: 2012; 57 4 821 829
65. Bolondi L., Burroughs A., Dufour J-F., et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis: 2012; 32 4 348 359
66. Salem R., Mazzaferro V., Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology: 2013; 58 6 2188 2197
67. Riaz A., Kulik L., Lewandowski R. J., et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology: 2009; 49 4 1185 1193
68. Gaba R. C., Lewandowski R. J., Kulik L. M., et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol: 2009; 16 6 1587 159
69. Iñarrairaegui M., Pardo F., Bilbao J. I., et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol: 2012; 38 7 594 601
70. Coldwell D., Sangro B., Wasan H., Salem R., Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol: 2011; 34 3 337 341
71. Leung T. W., Lau W. Y., Ho S. K., et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys: 1995; 33 4 919 924
72. Carr B. I. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl: 2004; 10 2 01 S107 S110
73. Carretero C., Munoz-Navas M., Betes M., et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol: 2007; 102 6 1216 1220
74. Geschwind J-FH, Salem R., Carr B. I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology: 2004; 127 5 01 S194 S205
75. Salem R., Lewandowski R. J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol: 2005; 16 12 1627 1639
76. Woodall C. E., Scoggins C. R., Ellis S. F., et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg: 2009; 208 3 375 382
77. Gil-Alzugaray B., Chopitea A., Iñarrairaegui M., et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology: 2013; 57 3 1078 1087